Dubé Eve, Gagnon Dominique, Kiely Marilou, Boulianne Nicole, Landry Monique
a Québec Institute of Public Health ; Québec , Canada.
Hum Vaccin Immunother. 2015;11(4):956-60. doi: 10.1080/21645515.2015.1009816.
A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.
2012 - 2013年流感季节期间,加拿大魁北克省向患有慢性疾病的2至17岁儿童提供了减毒活流感疫苗(LAIV)。尽管提供了该疫苗,但疫苗接种率较低。我们评估了参与2012 - 2013年活动的疫苗接种提供者对季节性流感疫苗接种和LAIV使用的看法和意见。超过70%的人认为LAIV安全有效,超过90%的人认为该疫苗受到家长和医护人员的欢迎。根据受访者的说法,家长对LAIV最常见的担忧与疫苗效力有关。参与流感疫苗接种诊所的疫苗接种提供者对LAIV接受度较高,但需要更多关于该疫苗及其使用建议的信息,以提高疫苗接种率。